Arthur Kuan, MS, joins the Lustgarten Foundation Board of Directors
UNIONDALE, N.Y., July 1, 2025 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the world's largest private funder of pancreatic cancer research, today announced the appointment of Arthur Kuan, MS, to its Board of Directors. Mr. Kuan is the Chairman and Chief Executive Officer of CG Oncology, a clinical-stage biotechnology company pioneering oncolytic immunotherapies for patients with urologic cancers.
"We are honored to welcome Arthur Kuan to the Lustgarten Foundation Board of Directors," said Linda Tantawi, CEO of the Lustgarten Foundation. "Arthur brings a unique perspective at the intersection of biotechnology innovation and clinical development. His leadership and insights will be instrumental as we continue to advance our strategic vision and shape the next generation of pancreatic cancer research."
Mr. Kuan has served as CEO of CG Oncology since 2016, guiding the company's strategy, clinical programs, and partnerships. Under his leadership, CG Oncology has advanced cretostimogene, its lead oncolytic immunotherapy candidate for bladder cancer through seven clinical programs including two phase 3 trials. He brings extensive experience in biotechnology company building, venture capital, and immuno-oncology innovation. Prior to CG Oncology, Mr. Kuan was a Founding Member at Ally Bridge Group, a global healthcare-focused investment group, and held roles at Themes Investment Partners and Dinova Capital. He holds a Master of Science in Biotechnology from Johns Hopkins University and a Bachelor of Arts in Biology from the University of Pennsylvania.
"I am incredibly proud to join the Lustgarten Foundation's Board of Directors," said Arthur Kuan, CEO of CG Oncology. "Pancreatic cancer remains one of the most urgent and intractable medical challenges. I am committed to helping drive innovative, patient-centered solutions and look forward to collaborating with the Foundation's leadership to accelerate progress and bring renewed hope to patients and families affected by this disease."
Mr. Kuan's passion for advancing cancer research is deeply personal. He lost his father to pancreatic cancer at the age of 52—a moment that reshaped his professional focus. "When my father passed away from pancreatic cancer, I knew I had to help patients like him—patients who urgently need more treatment options," he shared.
Pancreatic cancer represents only 3% of all cancers diagnosed in the United States each year, yet it is the third-leading cause of cancer-related deaths and is poised to become the second by 2030. And, while the five-year survival rate for all stages combined has reached an unprecedented high of 13%, thanks to Lustgarten's role as a driving force in every major advancement in pancreatic cancer research, this significantly lags behind all other major cancers. The Lustgarten Foundation continues to pursue what matters most: changing, extending, and saving patients' lives through our relentless focus on funding bold, innovative studies, guided by our esteemed Board of Directors.
Media Contact
Alexas Santiago, Lustgarten Foundation, 8455586314, [email protected], https://lustgarten.org/
SOURCE Lustgarten Foundation
Share this article